Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future

BreakingsMay 2 20:08

Express News | Guangzheng Ophthalmology: A contract has been signed with Sinqi Pharmaceutical to introduce 0.01% atropine sulfate eye drops

BreakingsApr 11 16:53

Express News | Guangzheng Ophthalmology: The company will soon introduce qualified low-concentration atropine drugs and apply them clinically

BreakingsApr 2 14:27

Guangzheng Ophthalmology (002524.SZ): Currently, no visual prevention and control products have been developed and produced

Gelonghui, March 29丨An investor asked Guangzheng Ophthalmology (002524.SZ) on the investor interactive platform. Regarding “whether your company researches and produces myopia prevention and control products,” the company replied that the company has not yet developed and produced vision prevention and control products. The company provides patients with myopia prevention and control diagnosis and treatment services and solutions, and has good cooperative relationships with mainstream myopia prevention and control product suppliers.

Gelonghui FinanceMar 29 17:46

A-share changes丨The concept of ophthalmology medicine bucked the trend and promoted eye medicine to another record high

Glonghui, March 21 | Guangzheng Ophthalmology went up and down in a straight line. Ho's Ophthalmology surged more than 10%, Sinqi Eye Medicine surged 7%, and reached another record high in the intraday period. Sharp Ace and Puri Ophthalmology were ahead of the curve. According to the news, Sinqi Pharmaceutical previously announced on March 11 that it obtained a drug registration certificate for atropine sulphate eye drops. The approved clinical indication is to slow the progression of myopia in children aged 6 to 12 with a spherical degree of -1.00D to -4.00D (astigmatism ≤ 1.50D, refractive error ≤ 1.50D).

Gelonghui FinanceMar 21 11:27

Guangzheng Ophthalmology (002524.SZ): 2023 pre-profit of 8 million yuan to 12 million yuan

Ge Longhui, January 29丨Guangzheng Ophthalmology (002524.SZ) announced the 2023 annual performance forecast. Operating income for the reporting period was 1060 million yuan to 1080 million yuan 767.4446 million yuan, up 38.12% to 40.73% over the same period of the previous year; net profit attributable to shareholders of listed companies was 8 million yuan to 12 million yuan, or -78.1776 million yuan in the same period last year; net profit after deducting non-recurring profit and loss was -4 million yuan to -2 million yuan, compared to -291.681 million yuan for the same period last year; basic per share Earnings of 0.02 yuan to 0.

Gelonghui FinanceJan 29 18:56